FEATURES OF CLINICAL MANIFESTATIONS, COURSE, OUTCOMES AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE REPUBLIC OF KAZAKHSTAN

Особенности клинических проявлений, течения, исходов и качества жизни, связанного со здоровьем, у пациентов с системной красной волчанкой в Республике Казахстан
Issayeva B.G. Aseeva E.A. Saparbayeva M.M. Issayeva S.M. Kulshymanova M.M. Kaiyrgali S.M. Amanzholova A.S. Bizhanova M.P. Kalykova M.B. Solovyev S.K. Akhtaeva N.S.
2022 Ima-Press Publishing House

Nauchno-Prakticheskaya Revmatologiya
2022 #60 Issue 6 602 - 611 pp.

Objective – to evaluate the features of clinical manifestations, course, outcomes and quality of life related to health in patients with systemic lupus erythematosus in the Republic of Kazakhstan. Patients and methods. The study included 102 patients with systemic lupus erythematosus (SLE) with a reliable diagnosis according to SLICC (2012). Disease activity was assessed by the SLEDAI 2K index, organ damage (IOD) by SLICC/ACR (2000). Statistical processing was carried out using SPSS 13 software (IBM Corp., USA). Variables with a parametric distribution are presented as М±SD, nonparametric – as a median (Me) [25th; 75th percentile]. Results and discussion. The cohort was dominated by female patients (98%), Asians (83.33%), young patients (33.85±10.58 years) with a disease duration of 5 [2; 9] years with high (30.8%) and very high (39.2%) degree of activity (SLEDAI-2K – 17.64±8.80 points). The debut of the disease was in 18.6% of patients in adolescence, it was characterized by an unfavorable course. Clinical manifestations of the disease: skin lesions (acute active and chronic forms) (98%), joints (79.4%), non-scarring alopecia (75.5%), neuropsychiatric disorders (49%), mucous membranes (46.1%), hematological (54.9%) and immunological disorders (100%). IOD: low – in 20.6%, medium – in 59.8%, high – in 9.8% of patients, 0 – in 9.8%, Risk factors for poor outcome were in 93.1% of patients. Assessment of health-related quality of life (HRQOL) in SLE patients showed a significant decrease on all scales. Correction of the treatment program, taking into account the factors of adverse outcome (FRNI), consisted in strengthening therapy with the inclusion of genetically engineered biological drugs (GEBP). Conclusion. SLE is a socially significant disease in Kazakhstan with a high incidence rate (101%) over 10 years (2009–2018). The cohort of SLE patients is dominated by young people, females. The duration of the disease is up to 5 years with a delayed verification of the diagnosis of SLE. Organ damage is already in the onset of the disease and the presence of FRNI of the disease in 93.1% of patients, which indicates the severity of the course, which requires early diagnosis and active involvement of pathogenetic treatment, including GEBD.

activity index , damage index , pathogenetic therapy , risk factors for adverse outcomes , systemic lupus erythematosus

Text of the article Перейти на текст статьи

Asfendiyarov Kazakh National Medical University, Töle Bi str., 94, Almaty, 005012, Kazakhstan
V.A. Nasonova Research Institute of Rheumatology, Kashirskoye Highway, 34A, Moscow, 115522, Russian Federation
City Rheumatological Center, Ayteke Bi str., 116, Almaty, 055556, Kazakhstan

Asfendiyarov Kazakh National Medical University
V.A. Nasonova Research Institute of Rheumatology
City Rheumatological Center

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026